Borealis Biosciences

Chronic kidney diseases are a severe and growing worldwide health challenge that affects 1 in 7 people.  Without effective treatments patients can experience kidney failure leading to dialysis and transplantation, a high burden to patients, families and the health care system. Despite recent advances for certain kidney disease patients, many forms of highly prevalent kidney diseases do not have effective treatments.

Borealis was founded on the premise that a convergence of scientific and translational breakthroughs will enable RNA therapeutics to address some of the largest untreated kidney diseases and beyond.  Borealis builds on the success of Chinook Therapeutics, a kidney disease company with a research site in Vancouver that was acquired by Novartis in 2023 for up to $3.5 billion. The Borealis team has strong leadership and academic advisors who were central to research at Chinook, together with additional leadership in the field of RNA therapeutics. We are headquartered in Vancouver, BC, with state-of-the-art wet labs for molecular and cellular biology, in vivo pharmacology, chemistry, DMPK, bioinformatics and analytical capabilities.

We are a creative and innovative team that strives for excellence in all we do and has fun along the way. Our core focus is on helping patients and advancing science. For more information on Borealis, check out our sites https://borealisbio.com & https://www.linkedin.com/company/borealis-biosciences-inc.